vs
Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and Qudian Inc. (HTT). Click either name above to swap in a different company.
Qudian Inc. is the larger business by last-quarter revenue ($1.1M vs $706.0K, roughly 1.5× Astria Therapeutics, Inc.). Qudian Inc. runs the higher net margin — 239.8% vs -4482.0%, a 4721.8% gap on every dollar of revenue.
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
Qudian Inc. is a China-based fintech service provider that mainly offers small consumer credit solutions, risk management technical services, and related digital financial products. Its core target users are young mass consumers across China, with all key business operations focused on the domestic Chinese market.
ATXS vs HTT — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $706.0K | $1.1M |
| Net Profit | $-31.6M | $2.6M |
| Gross Margin | — | 11.1% |
| Operating Margin | -4830.6% | -121.7% |
| Net Margin | -4482.0% | 239.8% |
| Revenue YoY | — | — |
| Net Profit YoY | -29.0% | — |
| EPS (diluted) | $-0.55 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $706.0K | — | ||
| Q3 24 | $0 | $1.1M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | $1.1M | ||
| Q3 23 | — | $559.9K | ||
| Q3 22 | — | $2.1M | ||
| Q2 22 | — | $2.2M | ||
| Q1 22 | — | $4.4M |
| Q3 25 | $-31.6M | — | ||
| Q3 24 | $-24.5M | $2.6M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $-1.4M | ||
| Q3 23 | — | $-3.4M | ||
| Q3 22 | — | $-12.6M | ||
| Q2 22 | — | $-1.3M | ||
| Q1 22 | — | $-3.1M |
| Q3 25 | — | — | ||
| Q3 24 | — | 11.1% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 61.0% | ||
| Q1 22 | — | 84.1% |
| Q3 25 | -4830.6% | — | ||
| Q3 24 | — | -121.7% | ||
| Q2 24 | — | -107.6% | ||
| Q1 24 | — | -129.9% | ||
| Q3 23 | — | -340.6% | ||
| Q3 22 | — | -272.1% | ||
| Q2 22 | — | -27.8% | ||
| Q1 22 | — | -32.9% |
| Q3 25 | -4482.0% | — | ||
| Q3 24 | — | 239.8% | ||
| Q2 24 | — | 187.1% | ||
| Q1 24 | — | -131.8% | ||
| Q3 23 | — | -612.3% | ||
| Q3 22 | — | -588.2% | ||
| Q2 22 | — | -58.1% | ||
| Q1 22 | — | -70.8% |
| Q3 25 | $-0.55 | — | ||
| Q3 24 | $-0.42 | $0.01 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.01 | ||
| Q3 23 | — | $-0.02 | ||
| Q3 22 | — | $-0.05 | ||
| Q2 22 | — | $-0.01 | ||
| Q1 22 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $227.7M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $233.3M | $225.2M |
| Total Assets | $271.9M | $246.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $227.7M | — | ||
| Q3 24 | $344.3M | $104.9M | ||
| Q2 24 | — | $112.8M | ||
| Q1 24 | — | $140.6M | ||
| Q3 23 | — | $183.4M | ||
| Q3 22 | — | $154.1M | ||
| Q2 22 | — | $168.3M | ||
| Q1 22 | — | $180.3M |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | $521.5K | ||
| Q1 22 | — | — |
| Q3 25 | $233.3M | — | ||
| Q3 24 | $341.7M | $225.2M | ||
| Q2 24 | — | $217.5M | ||
| Q1 24 | — | $218.9M | ||
| Q3 23 | — | $226.0M | ||
| Q3 22 | — | $225.5M | ||
| Q2 22 | — | $253.0M | ||
| Q1 22 | — | $269.4M |
| Q3 25 | $271.9M | — | ||
| Q3 24 | $361.6M | $246.8M | ||
| Q2 24 | — | $227.9M | ||
| Q1 24 | — | $234.9M | ||
| Q3 23 | — | $239.4M | ||
| Q3 22 | — | $249.6M | ||
| Q2 22 | — | $283.4M | ||
| Q1 22 | — | $296.3M |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 0.00× | ||
| Q1 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-32.3M | — | ||
| Q3 24 | $-28.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | — | ||
| Q3 24 | $-28.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | 0.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
